Earnings

EBIT and EBITDA

Earnings before interest and tax (EBIT) totaled €234.6 million, which was 43.4 percent below the figure for the prior-year period (H1 2021: €414.8 million). EBIT included budgeted purchase price allocation effects amounting to an expense of €45.0 million in the first half of 2022 (H1 2021: expense of €41.8 million). In the reporting period, there were also non-recurring items amounting to a total expense of €32.1 million (H1 2021: expense of €5.5 million) that essentially reflected impairment losses on assets of the Russian subsidiaries.

EBIT adjusted for non-recurring items and purchase price allocation effects (adjusted EBIT) decreased to €311.7 million (H1 2021: €462.2 million). The adjusted EBIT margin fell sharply to 5.6 percent as a result (H1 2021: 9.3 percent).

EBIT

in € million

Q2
2022

Q2
2021

Q1 – Q2
2022

in % of revenue

Q1 – Q2
2021

in % of revenue

EBIT

116.8

221.3

234.6

4.2%

414.8

8.4%

Adjustment by functional costs:

 

 

 

 

 

 

+ Cost of sales

11.1

9.4

28.6

0.5%

18.9

0.4%

+ Selling expenses and administrative expenses

13.3

15.1

34.4

0.6%

29.5

0.6%

+ Research and development costs

0.0

0.0

0.0

0.0%

0.1

0.0%

+ Other costs

0.2

1.4

14.2

0.3%

–1.1

–0.0%

Adjusted EBIT

141.4

247.2

311.7

5.6%

462.2

9.3%

adjusted for non-recurring items

1.6

5.0

32.1

0.6%

5.5

0.1%

adjusted for PPA items

23.0

20.9

45.0

0.8%

41.8

0.8%

Earnings before interest, tax, depreciation, and amortization (EBITDA) stood at €739.6 million in the reporting period (H1 2021: €873.9 million). Adjusted EBITDA came to €759.2 million (H1 2021: €879.5 million), giving an adjusted EBITDA margin of 13.7 percent (H1 2021: 17.7 percent).

EBITDA

in € million

Q2
2022

Q2
2021

Q1 – Q2
2022

in % of revenue

Q1 – Q2
2021

in % of revenue

EBITDA

366.5

452.7

739.6

13.4%

873.9

17.6%

Adjustment by functional costs:

 

 

 

 

 

 

+ Cost of sales

0.8

0.0

8.4

0.2%

0.0

0.0%

+ Selling expenses and administrative expenses

0.6

3.6

9.5

0.2%

6.6

0.1%

+ Research and development costs

0.0

0.0

0.0

0.0%

0.0

0.0%

+ Other costs

0.4

1.4

1.8

0.0%

–1.0

–0.0%

Adjusted EBITDA

368.2

457.7

759.2

13.7%

879.5

17.7%

adjusted for non-recurring items

1.7

5.0

19.7

0.4%

5.6

0.1%

adjusted for PPA items

0.0

–0.0

0.0

0.0%

0.0

0.0%